Q3 was another resilient quarter, slightly ahead of our expectations, with strong organic growth softening the impact of negative currency. For both 3m and 9m, sales increased 6% organically to CHF11.9bn and CHF35.5bn, respectively, while negative currency brought down the reported growth to 1% and 2%, respectively. The earnings numbers are not disclosed in quarterly releases. The sales outlook has been upgraded from low-to-mid single-digit to mid single-digit range, while the guidance for co
27 Oct 2015
Strong performance along with key R&D successes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong performance along with key R&D successes
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
27 Oct 2015 -
Author:
Kamla Singh -
Pages:
3
Q3 was another resilient quarter, slightly ahead of our expectations, with strong organic growth softening the impact of negative currency. For both 3m and 9m, sales increased 6% organically to CHF11.9bn and CHF35.5bn, respectively, while negative currency brought down the reported growth to 1% and 2%, respectively. The earnings numbers are not disclosed in quarterly releases. The sales outlook has been upgraded from low-to-mid single-digit to mid single-digit range, while the guidance for co